Get started
Titan Pharmaceuticals, Inc.Titan Pharmaceuticals, Inc.Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

TTNP chart


Full chart

TTNP upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.22 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−6.50 USD
Net income (FY)
‪−5.57 M‬ USD
Revenue (FY)
‪184.00 K‬ USD
Shares float
‪648.63 K‬
Beta (1Y)
−1.14

Employees


Employees (FY)
4
Change (1Y)
0
Revenue / Employee (1Y)
‪46.00 K‬ USD
Net income / Employee (1Y)
‪−1.39 M‬ USD

About Titan Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Weei Jye Chay
Headquarters
South San Francisco
Website
titanpharm.com
Founded
1992
FIGI
BBG000BTGSY7
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TTNP news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TTNP is 3.33 USD — it has decreased by −4.83% in the past 24 hours. Watch Titan Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Titan Pharmaceuticals, Inc. stocks are traded under the ticker TTNP.
TTNP stock has risen by 1.52% compared to the previous week, the month change is a −14.10% fall, over the last year Titan Pharmaceuticals, Inc. has showed a −53.45% decrease.
TTNP reached its all-time high on Sep 29, 2000 with the price of 1,293,069.29 USD, and its all-time low was 3.12 USD and was reached on Dec 26, 2024. View more price dynamics on TTNP chart.
See other stocks reaching their highest and lowest prices.
TTNP stock is 6.83% volatile and has beta coefficient of −1.14. Track Titan Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Titan Pharmaceuticals, Inc. there?
Today Titan Pharmaceuticals, Inc. has the market capitalization of ‪3.22 M‬, it has increased by 0.43% over the last week.
Yes, you can track Titan Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Titan Pharmaceuticals, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
TTNP net income for the last quarter is ‪−2.09 M‬ USD, while the quarter before that showed ‪−1.06 M‬ USD of net income which accounts for −97.45% change. Track more Titan Pharmaceuticals, Inc. financial stats to get the full picture.
No, TTNP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 4.00 employees. See our rating of the largest employees — is Titan Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Titan Pharmaceuticals, Inc. EBITDA is ‪−7.09 M‬ USD, and current EBITDA margin is ‪−3.89 K‬%. See more stats in Titan Pharmaceuticals, Inc. financial statements.
Like other stocks, TTNP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Titan Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Titan Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Titan Pharmaceuticals, Inc. stock shows the strong sell signal. See more of Titan Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.